Last reviewed · How we verify
Pandemic flu H5 mRNA vaccine
Pandemic flu H5 mRNA vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | Pandemic flu H5 mRNA vaccine |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (PHASE1, PHASE2)
- Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older (PHASE1, PHASE2)
- Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pandemic flu H5 mRNA vaccine CI brief — competitive landscape report
- Pandemic flu H5 mRNA vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Pandemic flu H5 mRNA vaccine
What is Pandemic flu H5 mRNA vaccine?
Pandemic flu H5 mRNA vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Pandemic flu H5 mRNA vaccine?
Pandemic flu H5 mRNA vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Pandemic flu H5 mRNA vaccine in?
Pandemic flu H5 mRNA vaccine is in Phase 1.